Detection of Urinary Molecular Marker Test in Urothelial Cell Carcinoma: A Review of Methods and Accuracy.
FGFR3
NMP22
UroVysion
bladder cancer detection
molecular marker test
urothelial carcinomas
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
04 Nov 2022
04 Nov 2022
Historique:
received:
10
10
2022
revised:
31
10
2022
accepted:
03
11
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Early detection of bladder cancer has a positive impact on prognosis. A variety of biomarkers have been developed to detect bladder tumors in urine early and reduce the need for cystoscopy. To detect bladder cancer, several methods are available, but their accuracy varies according to the sensitivity and specificity of each method. This review aims to highlight the established detection methods for bladder cancer based on the available literature. In addition, we aim to identify the combination of different effective detection methods that provides the highest degree of accuracy. In our study, a keyword retrieval method was used to search for appropriate English-language references. This bibliography has been indexed in PubMed and Scopus or has been found through systematic searches from 2015 to 2022. Based on an analysis of international guidelines, it has been revealed that there are numerous discrepancies and unresolved issues. The discovery of an ideal detection method for urothelial cell carcinoma biomarkers has been the subject of numerous efforts. In recent years, a wide range of off-label, experimental, novel, and combined approaches have been published on this topic. This review can contribute to the identification of accurate methods of detecting bladder cancer and highlight areas for future research that can be improved.
Identifiants
pubmed: 36359539
pii: diagnostics12112696
doi: 10.3390/diagnostics12112696
pmc: PMC9689047
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
Curr Urol Rep. 2017 Nov 13;18(12):100
pubmed: 29130146
Dis Markers. 2018 Jan 30;2018:5823870
pubmed: 29651327
J Urol. 2016 Oct;196(4):1021-9
pubmed: 27317986
Transl Androl Urol. 2021 Apr;10(4):1908-1917
pubmed: 33968678
Eur Urol. 2022 Jan;81(1):75-94
pubmed: 34511303
Cancer Sci. 2008 Apr;99(4):646-52
pubmed: 18377416
Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1271-1273
pubmed: 31030505
Urol Oncol. 2017 Aug;35(8):531.e15-531.e22
pubmed: 28366272
Urol Clin North Am. 2016 Feb;43(1):47-62
pubmed: 26614028
Onco Targets Ther. 2022 May 02;15:497-507
pubmed: 35529887
Biomolecules. 2021 Aug 16;11(8):
pubmed: 34439880
Sci Rep. 2015 Aug 26;5:13321
pubmed: 26306458
Ther Adv Urol. 2015 Dec;7(6):351-64
pubmed: 26622320
Pharmacol Res. 2020 Jan;151:104567
pubmed: 31770593
BMC Genomics. 2015 Sep 16;16:702
pubmed: 26376692
World J Urol. 2018 Dec;36(12):1981-1995
pubmed: 29931526
Curr Opin Urol. 2004 Sep;14(5):277-86
pubmed: 15300148
Int J Clin Oncol. 2018 Dec;23(6):1140-1147
pubmed: 29971622
J Cancer Res Ther. 2017;13(4):647-650
pubmed: 28901308
Urol Oncol. 2021 Jan;39(1):41-51
pubmed: 32919875
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Oncol Lett. 2016 Jan;11(1):795-797
pubmed: 26870286
Bladder Cancer. 2018 Oct 29;4(4):353-363
pubmed: 30417046
Urology. 1998 Oct;52(4):594-601
pubmed: 9763077
Ann Intern Med. 2015 Dec 15;163(12):922-31
pubmed: 26501851
J Urol. 2003 Jun;169(6):1975-82
pubmed: 12771702
Front Med (Lausanne). 2020 Aug 27;7:437
pubmed: 32974362
Cancer Treat Rev. 2021 Apr;95:102175
pubmed: 33721595
Diagnostics (Basel). 2020 Jun 08;10(6):
pubmed: 32521780
Asian J Urol. 2019 Jan;6(1):114-121
pubmed: 30775255
Urol Oncol. 2016 Oct;34(10):460-8
pubmed: 27368880
Curr Urol Rep. 2018 Oct 17;19(12):96
pubmed: 30328534
Urol Oncol. 2015 Feb;33(2):66.e25-31
pubmed: 25037483
Int J Mol Sci. 2021 Nov 28;22(23):
pubmed: 34884669
Cancers (Basel). 2020 May 29;12(6):
pubmed: 32485907
Dis Markers. 2016;2016:8205836
pubmed: 26924873
Indian J Urol. 2015 Oct-Dec;31(4):273-82
pubmed: 26604437
Indian J Urol. 2015 Oct-Dec;31(4):283-8
pubmed: 26604438
Med Oncol. 2018 Nov 29;36(1):10
pubmed: 30499061
Curr Opin Urol. 2004 Sep;14(5):259-64
pubmed: 15300145
Front Immunol. 2020 Nov 05;11:575258
pubmed: 33224141
J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053
pubmed: 30181416
Crit Rev Oncol Hematol. 2022 Feb;170:103577
pubmed: 34999017
Cancer Treat Rev. 2020 Jun;86:102000
pubmed: 32203842
Front Oncol. 2018 Sep 07;8:362
pubmed: 30245975
Can J Urol. 2017 Feb;24(1):8620-8626
pubmed: 28263126
Eur Urol. 2005 Jun;47(6):736-48
pubmed: 15925067
Clin Chim Acta. 2004 Feb;340(1-2):57-65
pubmed: 14734196
J Urol. 1998 Jun;159(6):1876-80
pubmed: 9598479